Showing results (31-40 of 62) with videos related to
Sort By:
Pageof 7
The Lancet. Infectious Diseases|October 22, 2011
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyJean-Michel Molina, Anthony Lamarca, Jaime Andrade-Villanueva, et al.Sexually Transmitted Diseases|July 26, 2006
HIV and syphilis: when to perform a lumbar punctureAgnès Libois, Stéphane De Wit, Bénédicte Poll, et al.The Journal of Antimicrobial Chemotherapy|April 26, 2012
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsMark Nelson, Gerardo Amaya, Nathan Clumeck, et al.AIDS (London, England)|April 7, 2007
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimenAlessandro Cozzi-Lepri, Andrew N Phillips, Lidia Ruiz, et al.AIDS (London, England)|May 5, 2012
Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patientsSophie Bouchat, Jean-Stéphane Gatot, Kabamba Kabeya, et al.AIDS (London, England)|July 2, 2014
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsDavid A Cooper, Jayvant Heera, Prudence Ive, et al.Basic & Clinical Pharmacology & Toxicology|October 4, 2007
Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trialsUlrik S Justesen, Zoe Fox, Court Pedersen, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2006
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trialPedro Cahn, Jorge Villacian, Adriano Lazzarin, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 13, 2004
Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001Joke Snoeck, Kristel Van Laethem, Philippe Hermans, et al.The New England Journal of Medicine|November 8, 2013
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infectionSharon L Walmsley, Antonio Antela, Nathan Clumeck, et al.Pageof 7